Crage Medical Co., Limited

Shanghai Yile Biotechnology Co., Ltd.

Carsgen Therapeutics Limited

Cafa Therapeutics Limited

Xiumei Cai

Huamao Wang

Bo Song

Ruping Dai

Hongxia Zhao

Yinyu Zhu

Xinfu Zhou

Changqi Li

Yuanmei Chen

Disclosed are a chimeric antigen receptor (CAR) targeting CLD18A2, and preparation method and use thereof. The extracellular binding region of the CAR comprises a protein specifically recognizing CLD18A2. The immune effector cell modified by the CAR can be used to treat tumors such as pancreatic cancer and stomach cancer.

Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof

An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.

Polypeptide and antibody bound to polypeptide

Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.

GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof

Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (proBDNF). The binding molecule for proBDNF, especially a monoclonal antibody against proBDNF, can be used to prevent, mitigate or treat autoimmune diseases.

Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor

Growing community of inventors

Shanghai, China

Xiumei Cai